survival

Kerri FitzgeraldMantle Cell Lymphoma | October 5, 2022

Event-free survival at 24 months may become an important clinical endpoint in mantle cell lymphoma in the future.

Kerri FitzgeraldMyelodysplastic Syndromes | October 4, 2022

A study showed "unexpected" results related to race and MDS survival...

Kerri FitzgeraldAcute Myeloid Leukemia | October 3, 2022

The efficacy of enasidenib in patients with AML depends on the mutation type.

Kerri FitzgeraldAggressive B-Cell Lymphoma | September 13, 2022

The addition of brentuximab vedotin improved survival in Hodgkin lymphoma.

Cecilia BrownAggressive B-Cell Lymphoma | August 8, 2022

A new model that makes use of a promising imaging biomarker can predict diffuse large B-cell lymphoma relapse and survival ...

Leah SherwoodAcute Myeloid Leukemia | June 29, 2022

The expression patterns and clinical significances of CD300s in cancers are still not well understood.

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University